To reinforce this ongoing doubt creeping into some holders thoughts given the vacuum that has been created by no peer review, the FDA have not only reviewed the preclinical data, clinical data and animal studies in a dossier submission of >10k pages they have also awarded Fast Track designation given the promising preliminary results.
Ann: PAR Appoints Business Development Consultant, page-308
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $323.1K | 1.612M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 324 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 52928 | 5 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |